-+ 0.00%
-+ 0.00%
-+ 0.00%

Cellectis highlights cema-cel ALPHA3 interim data showing higher MRD clearance in LBCL

PUBT·04/13/2026 20:30:48
Listen to the news
Cellectis highlights cema-cel ALPHA3 interim data showing higher MRD clearance in LBCL
  • Cellectis highlighted interim futility analysis results already disclosed from Allogene’s pivotal ALPHA3 trial of cema-cel as first-line consolidation in large B-cell lymphoma.
  • Readout showed cema-cel arm produced stronger disease clearance than observation, supporting continued development of off-the-shelf CAR-T approach.
  • Safety profile to date appeared favorable, supporting outpatient use with no major treatment-related complications reported at cutoff.
  • Allogene targets completion of enrollment by end-2027, with interim event-free survival analysis planned for mid-2027.
  • Positive final results could support a BLA filing, with Cellectis eligible for up to USD 340 million in milestones under Servier agreement plus low double-digit royalties on net sales.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectis SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604131630PRIMZONEFULLFEED9688832) on April 13, 2026, and is solely responsible for the information contained therein.